Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
about
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsAlterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant SchizophreniaAntipsychotic dosing: found in translationNeuroleptic discontinuation syndromes.Clozapine: Current perspective.Antipsychotic dosing: how much but also how often?The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.The nature of relapse in schizophrenia.Supersensitivity psychosis and its response to asenapine in a patient with delusional disorderWithdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.Pharmacologic features and effects of neurolepticsSuccessful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophreniaBehavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition.Antipsychotic discontinuation syndromes: a narrative review of the evidence and its integration into Australian mental health nursing textbooks.The need for experience focused counselling (EFC) with voice hearers in training and practice: a review of the literature.A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.Rebound psychoses following the discontinuation of a high potency neuroleptic.Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.Neuroleptics under high risk conditions.Drug strategies and treatment-resistant schizophrenia.[Clinical and neurobiological aspects of long-term administration of psychotropic drugs]Targeted intermittent treatment in chronic schizophreniaMechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.The pharmacoepidemiology of treatment-refractory schizophrenia.Metoclopramide-induced supersensitivity psychosis.Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.The oft-times overlooked "pharmacologic" relapse in schizophrenia.Antipsychotic drugs up-regulate tryptophan hydroxylase in ADF neurons of Caenorhabditis elegans: role of calcium-calmodulin-dependent protein kinase II and transient receptor potential vanilloid channel.Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.Brain catecholamines in schizophrenia -- a good case for noradrenaline.Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?The long-term treatment of schizophrenia with antipsychotics: a perennial debate.
P2860
Q26745506-AECA029E-60D2-4729-A38D-69326C31C830Q26773403-83BA7E41-0B83-4A8A-8055-3F0698FEC226Q26863343-CF4F78AB-968F-44C9-BB6C-52853175A988Q33538378-D4A6FA99-B874-4BE3-9DE2-AC4A3DC38DE3Q34021447-96585858-28CE-4281-9B47-82A41C7B706EQ34023214-B24640F0-985A-432B-B802-983733F5B542Q34418847-A53F5EAD-FC90-469D-A62E-56C18C23732AQ34523396-EA6AC98C-E062-4E2D-8F68-86F30B99EE89Q34525841-27135C50-D4FA-4E0A-B3AF-B2D4D7D1203AQ34581127-7728ED9C-FA85-4FCA-8A80-069AAE1F336CQ34588453-34FD50F6-2DBC-473B-BB13-1A6B4C902D5EQ34653803-D0D70534-3A26-4853-B81A-091EFACEA190Q35776516-EFA79938-B5FB-46EE-BA2F-4A0F1001749FQ36395488-8CA5018F-D204-4178-B1F5-9C071C4EE4FEQ37218474-04918F1C-98AC-4C58-9175-68A388C20591Q38064970-FE5B4BFF-298E-4957-9C70-EE9C03ADCCCCQ38109947-6D0255E6-AF15-4262-9CEE-89EE8ED0CAEDQ38708602-DCEAD612-82A8-4429-BD2A-16C807A539A2Q38855787-AA26BBF6-A001-4CF3-A812-23F7969CE9A9Q39170484-304756A4-E0A7-46FF-A05B-F52937A4FFB3Q39749536-F4E03FA9-32C0-49DE-ADA9-0440AF142EFDQ40047127-460038CC-10CF-423F-B23E-8598F1904A7CQ40091675-F4CF5B41-D7A1-4119-9B3B-997DF21CC99FQ41047105-7F10CF9A-EE41-45E3-A7D2-29330E46BE0DQ41134797-CF120672-96EE-4443-916B-9154505D18FDQ41156644-B9DBDDC2-0EB7-4925-B47E-E6E565D7E5C4Q41846717-D56108C3-8EE7-46EF-9D84-8CFAD5BA1271Q41858651-D0C4D040-3C26-41BF-9428-D11627EAE8EBQ43757507-5B16BD15-CF8E-4241-932B-4BD66E6968BBQ44114532-37208649-D8A9-4F78-8675-6EC2F4882432Q44597801-A348CCC0-C853-4FC3-8430-DF786F25F193Q46558915-AA61A6FA-836F-44E6-BCDC-5F2B87759878Q46625116-BD265417-BB4D-453B-8B66-D297B1877861Q47618934-24C3B1C2-D028-4382-86ED-775B614E5333Q48886768-DC627940-2322-43FD-9A58-56493231FC8EQ52652401-7824BF1F-7137-4E42-BEC2-27EE3A4A34FCQ55023835-1219E287-79A6-4004-BAE1-7D3B1271D8F2Q55104225-84AFD4D9-A108-471F-885F-F2FB36DB2587Q55338845-D5AE7697-CCD2-4D5C-BCB1-F6E07C8A5472
P2860
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
description
1980 nî lūn-bûn
@nan
1980 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@ast
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@en
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@nl
type
label
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@ast
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@en
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@nl
prefLabel
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@ast
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@en
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@nl
P356
P1476
Neuroleptic-induced supersensi ...... pharmacologic characteristics.
@en
P2093
P356
10.1176/AJP.137.1.16
P407
P577
1980-01-01T00:00:00Z